论文部分内容阅读
Threshold制药公司宣布他索替尼(tarloxotinib)项目2次Ⅱ期临床试验证实概念研究的中期结果,计划将重点移至先进的依伏磷酰胺(evofosfamide)项目和早期开发的候选药物TH-3424。他索替尼项目包括2次Ⅱ期临床试验证实概念的研究。它是一种前药,在严重缺低氧下选择性释放共价键(不可逆),为EGFR酪氨酸激酶抑制剂。用实体瘤反应评价标准测定疗效。第1次Ⅱ期临床试验入选复发性或转移性头颈部或皮肤鳞
Threshold Pharmaceuticals Inc. announced that two of his phase II clinical trials of tarloxotinib project confirmed the interim results of the concept study and plans to move to the advanced evofosfamide project and the early-development drug candidate TH-3424. The Tasitinib project includes two Phase II clinical trials confirming the concept study. It is a prodrug that selectively releases covalent bonds (irreversible) in the severe absence of oxygen, as an EGFR tyrosine kinase inhibitor. Efficacy was assessed using solid tumor response evaluation criteria. The first phase Ⅱ clinical trial of recurrent or metastatic head and neck or skin scale